In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.

Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug ...

Multi-year partnership with France's Servier will use Insilico's AI platform to explore novel cancer drugs Newly Hong ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...

The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, science-forward drug development. By reducing reliance on animal models and ...

Vin Singh Founder and Chief Executive Officer BullFrog AI Holdings, Inc.